Antiepileptik İlaçlar
Özet
Epilepsi tedavisinde temel amaç, yan etkileri minimize ederek hastanın nöbetsiz bir yaşama kavuşmasını sağlamak ve kişiye özel ilaç seçimi yapmaktır. Antiepileptik ilaçlar, etki mekanizmalarına ve tarihsel gelişimlerine göre sınıflandırılmakta olup, her birinin endikasyonları, kontrendikasyonları ve farmakokinetik özellikleri tedavi başarısı için hayati önem taşır. İlaç seçimi sırasında hastanın yaşı, cinsiyeti ve eşlik eden hastalıkları gibi bireysel değişkenler göz önünde bulundurularak sodyum kanalı modülatörleri, GABA inhibitörleri veya çoklu mekanizmalı ajanlar arasında en uygun tercih yapılmalıdır. Tedavi süreci boyunca olası yan etkilerin ve ilaç etkileşimlerinin yakın takibi, özellikle çocukluk çağı epilepsileri gibi hassas gruplarda tedavi başarısını belirleyen temel unsurdur.
The primary goal of epilepsy treatment is to achieve a seizure-free state for the patient without significant side effects, necessitating a personalized approach to medication selection. Antiepileptic drugs are classified based on their historical development and mechanisms of action, such as sodium channel modulation or GABA enhancement, which are crucial for determining their therapeutic efficacy. Effective management requires carefully considering individual patient factors—including age, comorbidities, and lifestyle—while monitoring for complex drug interactions and potential adverse effects. Ongoing assessment and careful titration are essential, particularly when using specific agents for conditions like infantile spasms or managing chronic epilepsy in pediatric populations.
Referanslar
Carcak N, Ozkara C. Seizures and antiepileptic drugs from pathophysiology to clinical practice. Curr Pharm Des. 2017;23(42):6376-6388.
White, H. Steve and Smith, Misty D. and Wilcox, Karen S. Proposed mechanisms of action of currently available antiseizure drugs. Pellock’s Pediatric Epilepsy: New york: Springer Publishing Company ;2017 p. 585-602.
Gupta M, Tripp J. Phenytoin. [Updated 2020 Jul. 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
Cloyd JC, Gumnit RJ, McLain W. Status epilepticus. The role of intravenous phenytoin. JAMA.1980; 244: 1479–1481.
Anderson RJ. The little compound that could: How phenytoin changed drug discovery and development. Mol Interv 2009; 9(5): 208-14.
Johannessen LC, Johannessen S, Tomson T. Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. Adv. Drug Deliv. Rev. 2012; 64(10): 896-910.
Contınuum MM. American Academy of Neurology 2019;25(2, epılepsy):508–536.
Polat I, Karaoglu P, Ayanoglu M, Yis U, Hiz S. Life-threatening and rare adverse effects of phenytoin. Pediatr Emerg Care. 2015; 31(7): e3.
Iorga A, Horowitz BZ. Phenytoin Toxicity. [Updated 2020 Nov 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK482444/.
Spengler RF, Arrowsmith JB, Kilarski DJ, Buchanan C, Von Behren L, Graham DR. Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors. Arch. Intern Med. 1988;148(6):1329-33.
Maria BL. Current pharmacotherapy for pediatric seizures and epilepsy. Management in child neurology, 3rd ed. London: Hamilton. 2005. p.174-81
Luer MS. Fosphenytoin. Neurol Res.1998;20:178–182.
Jamerson BD, Dukes GE, Brouwer KL, et al. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy. 1994; 14:47–52.
Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum Psychopharmacol. 2009; 24(1):19-28.
Panayiotopoulos CP. Pharmacopoeia. A clinical guide to epileptic syndromes and their treatment, 2nd Edition, London: Springer Publication. 2009;565-627.
Hmouda H, Ben Salem C, Grira M, Slim R, Bouraoui K. Carbamazepine-induced urinary retention. Br. J. Clin. Pharmacol. 2007;64(6):833-4.
Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008; 9(10):1543-6.
Albani F, Grassi B, Ferrara R, et al. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure.2004;13:254–263.
Davanzo P, Nikore V, Yehya N, et al. Oxcarbazepine treatment of juvenile-onset bipolar disorder. J Child Adolesc Psychopharmacol. 2004; 14:344–345.
Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia. 2004;45: 895–907.
Theis JG, Sidhu J, Palmer J, et al. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology. 2005;30: 2269–2274.
Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics. 1993; 24:339–340.
Binnie CD. Lamotrigine. Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott-Raven; 1997:1531–1540.
Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol. 1997;12: S10–S15.
Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998; 29:147–154.
Snead OC, Hosey LC. Treatment of epileptic falling spells with ethosuximide. Brain Dev. 1987; 9:602–604.
Schmidt D, Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf. 2000; 22:467–477.
Glauser TA. Idiosyncratic reactions: new methods of identifying high-risk patients. Epilepsia. 2000;41 Suppl 8: S16-29.
Teoh PC, Chan HL. Lupus-scleroderma syndrome induced by ethosuximide. Arch. Dis. Child. 1975;50(8):658-61
Schulz DW, MacDonald RL. Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions. Brain Res. 1981;209(1):177–188.
French-Mullen JM, Barker JL, Rogawski MA. Calcium current block by (-)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital in acutely isolated hippocampal CA1 neurons: comparison with effects on GABA-activated Cl- current. J Neurosci. 1993;13(8):3211–3221.
Suddock JT, Cain MD. Barbiturate Toxicity StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL):2020. https://www.ncbi.nlm.nih.gov/books/NBK499875/
Segura-Bruna N, Rodriguez-Campello A, Puente V. Valproate-induced hyperammonemic encephalopathy. Acta. Neurol. Scand. 2006;114(1):1–7.
Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 1987;80(2):165–174.
Lennox WG. Brain injury, drugs and environment as causes of mental decay in epilepsy. Am. J. Psychiatry. 1942; 99:174–180.
Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br. Med.J. 1970;4(5727):73–76.
Morkunas AR, Miller MB. Anticonvulsant hypersensitivity syndrome. Crit Care Clin. 1997;13(4):727–739.
Wilson KC, Reardon C, Theodore AC. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving i.v. benzodiazepines: a case series and prospective, observational pilot study. Chest. 2005 ;128 (3):1674–1681.
Frey H-H. Experimental evidence for the development of tolerance to anticonvulsant drug effects. New York: Raven. Press.; 1986 :7–16.
Hernandez TD, Heninger C, Wilson MA. Relationship of agonist efficacy to changes in GABA sensitivity and anticonvulsant tolerance following chronic benzodiazepine ligand exposure. Eur. J. Pharmacol.1989; 170 (3):145–155.
Ramsey-Williams VA, Wu Y, Rosenberg HC. Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam. Pharmacol. Biochem. Behav.1994; 48 (3): 765–772.
Biggio G, Dazzi L, Biggio F, et al. Molecular mechanisms of tolerance to and withdrawal of GABA(A) receptor modulators. Eur. Neuropsychopharmacol. 2003;13(6): 411 – 423
Specht U, Boenigk HE, Wolf P. Discontinuation of clonazepam after long-term treatment. Epilepsia 1989; 30: 458 – 463.
Gastaut H, Low MD. Antiepileptic properties of clobazam, a1-5 benzodiazepine, in man. Epilepsia.1979; 20: 437 – 446.
Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: avoid tolerance. J. Neurol. Neurosurg. Psychiatry. 1984; 47: 1279 – 1282.
Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet .1982; 2: 71 – 73.
Khosroshahi N, Faramarzi F, Salamati P, et al. Diazepam versus clobazam for intermittent prophylaxis of febrile seizures. Indian J. Pediatr. 2011; 78 (1): 38 – 40.
Jensen HS, Nichol K, Lee D, et al. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α- versus α-GABA(A)-receptor complexes. PLoS One. 2014; 9: e88456.
Hammer H, Ebert B, Jensen HS, et al. Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytes. PLoS One. 2015; 10: e0120239.
Jullien V, Chhun S, Rey E, et al. Pharmacokinetics of clobazam and N-desmethylclobazam in children with Dravet syndrome receiving concomitant stiripentol and valproic acid. Clin. Pharmacokinet. 2015; 54 (5): 327 – 336.
Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy of infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008; 49 (2): 343 – 348.
Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox–Gastaut syndrome. Epilepsia. 2009; 50: 1158 – 1166.
Obeid T, Panayiotopoulos CP. Clonazepam in juvenile myoclonic epilepsy. Epilepsia. 1989; 30: 603 – 606.
Mantoan L, Wlaker M. Treatment options in juvenile myoclonic epilepsy. Curr.Treat. Options Neurol. 2011; 13 (4): 355 – 370.
Mikkelsen B, Birket-Smith E, Brandt S, et al. Clonazepam in the treatment of epilepsy. Arch. Neurol .1976; 33: 322 – 325.
Sato S, Penry JK, Dreifuss FE, et al. Clonazepam in the treatment of absence seizures: a double-blind clinical trial. Neurology. 1977; 27: 371.
Sato S, Malow BA. Benzodiazepines: clonazepam. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995: 725 – 734.
Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J. Clin. Psychiatry.1987; 48 (suppl): 4 – 11.
Seree EJ, Pisano PJ, Placidi M, et al. Identification of human and animal cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993; 7: 69 – 75.
Baruzzi A, Michelucci R, Tassinari CA. Benzodiazepines: nitrazepam. New York, NY : Raven Press; 1995 : 735 – 749.
Suzuki Y, Edge J, Mimaki T, et al. Intermittent clonazepam treatment prevents anticonvulsant tolerance in mice. Epilepsy Res. 1993; 15: 15 – 20.
Pesaturo K.A., Spooner L.M., Belliveau, P. (2011). Vigabatrin for Infantile Spasms. Pharmacotherapy, 31(3), 298–311.
Ochoa JG. Antiepileptic Drugs. In: Benbadis SR, ed. Medscape. 2017;1-36.
Armijo JA, Arteaga R, Valdizán EM, et al. Coadministration of vigabatrin and valproate in children with refractory epilepsy. Clin Neuropharmacol. 1992; 15:459–469.
Reidenberg P, Glue P, Banfield CR, et al. Pharmacokinetic interaction studies between felbamate and vigabatrin. Br J Clin Pharmacol.1995;40:157–160.
Majkowski J. Interactions between new and old generations of antiepileptic drugs. Epileptologia. 1994;2(Suppl 1):33–42.
Browne TR, Mattson TH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology.1987;37:184–189.
Kopp P.: The complexity of human interactions. 2001 Times. 97(13):45-8.
Messer R, Knupp KG. Infantile Spasms: opportunities to ımprove care. Semin neurol. 2020 Apr;40(2):236-245.
Chiron C. Stiripentol and vigabatrin current roles in the treatment of epilepsy. Expert Opin. Pharmacother. 2016 Jun;17(8):1091-101.
Giardina WJ. Anticonvulsant action of tiagabine, a new GABA-uptake inhibitor. J Epilepsy. 1994;7(3):161–166.
Dworkin RH, Corbin AE, Young JP Jr., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8): 1274–1283.
Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533–40.
Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. 2005;20(Suppl 1): S1–S56.
Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 2007;9(4):353–412.
Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs. 2004;18(3):133–156.
McDonald DG, Najam Y, Keegan MB, et al. The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. Seizure. 2005;14(2): 112–116.
Tallian KB, Nahata MC, Lo W, Tsao CY. Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. J. Clin. Pharm. Ther. 2004;29(6):511–515.
Mills JK, Ruslan NE, Lewis TG, et al. Retention rate of gabapentin in children with intractable epilepsies at 1 year. Seizure. 2012;21(1):28–31.
Holmes, Gregory L. and Pearl, Phillip L. Gabapentin and pregabalin pellock’s pediatric epilepsy new york: springer publishing company;2017 p. 815—826.
Glauser TA. Effects of antiepileptic medications on psychiatric and behavioral comorbidities in children and adolescents with epilepsy. Epilepsy Behav. 2004;5(Suppl 3): S25–S32.
Daoud AS, Zaki M, Shakir R, et al. Effectiveness of sodium valproate in the treatment of Syndenham chorea. Neurology. 1990; 40:1140–1141.
Kerwin RW, Olpe HR, Schmutz M. The effect of sodium-N-dipropylacetate on GABA dependent inhibition of rat cortex in vivo. Br. J. Pharmacol. 1980; 71:545–551
Franceschetti S, Hamon B, Heinemann U. The action of valproate on spontaneous epileptiform activity in the absence of synaptic transmission and on evoked changes on [Ca++] and [K+] in the hippocampal slice. Brain Res. 1986;386:1–11.
Löscher W. Valproic acid: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:767–779.
Bourgeois BFD. Pharmacologic interactions between valproate and other drugs. Am. J. Med. 1988;84(Suppl 1A):29–33.
Levy RH, Moreland TA, Morselli PL, et al. Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia. 1984; 25:338–345.
Theis JGW, Koren G, Daneman R, et al. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol. 1997; 12:208–213.
Suganuma T, Ishizaki T, Chiba K, et al. The effect of concurrent administration of valproate sodium on phenobarbital plasma concentration/dosage ratio in pediatric patients. J Pediatr. 1981; 99:314–317.
Lundberg B, Nergardh A, Boreus LO. Plasma concentrations of valproate during maintenance therapy in epileptic children. J Neurol. 1982; 228:133–141.
Dinesen H, Gram L, Anderson T, et al. Weight gain during treatment with valproate. Ada.Neurol Scand. 1984; 70:65–69.
Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implications for weight gain. Metabolism. 1992; 41:666–670.
König SA, Siemes H, Bläker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia. 1994; 35:1005–1015.
Camfield PR. Pancreatitis due to valproic acid. Lancet. 1979; 1:1198–1199.
Haidukewych D, John G, Zielinski JJ, et al. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther Drug Monit. 1985;7: 290–294.
Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001; 56:1405–1409.
Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev. 1996;18(2):105–109.
Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J. Pediatr. Hematol. Oncol. 2000; 22:62–65.
Isojärvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med. 2001; 111:290–296.
Brown SD, Wolf HH, Swinyard EA, et al. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia. 1993;34(Suppl 2):122–123.
Herrero AI, del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42(2):210–220.
Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(Suppl 1): S52–S60.
Petroff OA, Hyder F, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999;52(3):473–478.
White HS, Brown SD, Skeen GA, Twyman RA. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons. Epilepsia. 1995;36(Suppl 4):34.
Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004;46(8):1097–1104.
Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate in comparison with other new antiepileptic drugs. Epilepsia. 1994;35(Suppl 8):54.
Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996;37(8):774–780.
Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during mono-therapy and concomitant therapy. Epilepsia. 1997;38(3): 324–333.
Trokendi XR prescribinginformation. www.trokendixr.com/assets/sites/3/2015/05/trokendi-prescribing-information.pdf.
Qudexy XR full prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122 s000lbl.pdf. Accessed February 15, 2016.
Guerrini R, Carpay J, Groselj J, et al. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure. 2005;14(6):371–380.
Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(Suppl 2): S18–S22.
Majkowski J, Neto W, Wapenaar R, van Oene J. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia. 2005;46(5):648–653.
Labate A, Colosimo E, Gambardella A, et al. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure. 2006; 15:214–218.
Kumar A, Maini K, Kadian R. Levetiracetam. [Updated 2020 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL) statpearls publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK499890
Glauser TA, Ayala R, Elterman RD, et al. Doubleblind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006; 66:1654–1660
Glauser TA, Pellock JM, Bebin EM. Efficacy and safety of levetiracetam in children with partial seizures: an open label trial. Epilepsia. 2002; 43:518–524
Major P, Greenberg E, Khan A, Thiele EA. Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results. Epilepsy Behav. 2008; 13:557e559.
Mahmoud A, Tabassum S, Al Enazi S, Lubbad N et al. Amelioration of levetiracetam-ınduced behavioral side effects by pyridoxine. A randomized double blind controlled study. Pediatr. Neurol. 2021; 119:15-21.
Christidis D, Kalogerakis D, Chan TY, Mauri D, Alexiou G, Terzoudi A. Is primidone the drug of choice for epileptic patients with QT-prolongation? A comprehensive analysis of literature. Seizure. 2006 Jan;15(1):64-6.
Ochoa JG. Antiepileptic Drugs. In: Benbadis SR, ed. Medscape. 2017;1-36.
Lenkapothula N, Cascella M. Primidone. [Updated 2021 Mar 14]. In: StatPearls [Internet]. Treasure Island (FL) statpearls publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK562297
Windorfer A, Sauer W. Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate. Neuropädiatrie. 1977;8(1):29–41.
Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose short-duration corticotropin therapy for infantile spasms. J. Pediatr. 1994;124 (Pt 1):803–806.
Go CY, MacKay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974–1980
MacKay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62(10):1668–1681.
Hrachovy RA, Frost JD Jr, Kellaway P, Zion T. Doubleblind study of ACTH vs prednisone therapy in infantile spasms. J. Pediatr. 1983; 103 (4): 641 – 645.
Snead OC, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983; 33 (8): 966 – 970.
Lang D, Muhler E, Kupferschmid C, et al. Cardiac hypertrophy secondary to ACTH treatment in children. Eur J Pediatr. 1984;142(2):121–125.
Riikonen R, Amnell G: Psychiatric disorders in children with earlier infantile spasms. Dev. Med. Child Neurol. 1981; 23:747-760.
Jones, Kevin C. and Snead, O. Carter and RamachandranNair, Rajesh: acth and steroids. Pellock’s pediatric epilepsy New York, Springer Publishing Company 2017; p729—744.
